Do analysts rate CUE or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 210.05%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend DYAI or LIXT?

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 210.05%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Dyadic International (DYAI) Competitors

$0.97 +0.03 (+2.88%)

Closing price 07/6/2026 04:00 PM Eastern

Extended Trading

$0.96 0.00 (-0.27%)

As of 07/6/2026 07:09 PM Eastern

Compare

DYAI vs. CUE, PLYX, ALDX, PEPG, and LIXT

Should you buy Dyadic International stock or one of its competitors? MarketBeat compares Dyadic International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyadic International include Cue Biopharma (CUE), Polaryx Therapeutics (PLYX), Aldeyra Therapeutics (ALDX), PepGen (PEPG), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.

How does Dyadic International compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Cue Biopharma has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 210.05%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts plainly believe Dyadic International is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Dyadic International had 7 more articles in the media than Cue Biopharma. MarketBeat recorded 7 mentions for Dyadic International and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Neutral
Dyadic International	Neutral

Dyadic International has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	4.97	-$26.60M	-$5.58	N/A
Dyadic International	$3.09M	11.41	-$7.36M	-$0.23	N/A

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 20.9% of Dyadic International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cue Biopharma has a net margin of -59.65% compared to Dyadic International's net margin of -192.40%. Cue Biopharma's return on equity of -98.30% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats Cue Biopharma on 9 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Dyadic International (NASDAQ:DYAI) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Polaryx Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 277.36%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 210.05%. Given Polaryx Therapeutics' higher possible upside, equities analysts plainly believe Polaryx Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Polaryx Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Polaryx Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Dyadic International	-192.40%	-1,005.45%	-77.64%

Polaryx Therapeutics has higher earnings, but lower revenue than Dyadic International. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A
Dyadic International	$3.09M	11.41	-$7.36M	-$0.23	N/A

In the previous week, Dyadic International had 7 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 7 mentions for Dyadic International and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Dyadic International	Neutral

28.0% of Dyadic International shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Dyadic International beats Polaryx Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Dyadic International compare to Aldeyra Therapeutics?

Dyadic International (NASDAQ:DYAI) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Aldeyra Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Aldeyra Therapeutics' return on equity of -57.34% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Dyadic International has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	11.41	-$7.36M	-$0.23	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

In the previous week, Dyadic International had 6 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 7 mentions for Dyadic International and 1 mentions for Aldeyra Therapeutics. Dyadic International's average media sentiment score of 0.00 equaled Aldeyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Aldeyra Therapeutics	Neutral

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 210.05%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 141.23%. Given Dyadic International's stronger consensus rating and higher possible upside, equities analysts plainly believe Dyadic International is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dyadic International has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Summary

Dyadic International beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Dyadic International compare to PepGen?

PepGen (NASDAQ:PEPG) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Dyadic International had 7 more articles in the media than PepGen. MarketBeat recorded 7 mentions for Dyadic International and 0 mentions for PepGen. PepGen's average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score.

Company	Overall Sentiment
PepGen	Neutral
Dyadic International	Neutral

58.0% of PepGen shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 20.9% of Dyadic International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PepGen has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. PepGen's return on equity of -59.89% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Dyadic International	-192.40%	-1,005.45%	-77.64%

PepGen presently has a consensus price target of $11.50, indicating a potential upside of 508.47%. Dyadic International has a consensus price target of $3.00, indicating a potential upside of 210.05%. Given PepGen's stronger consensus rating and higher probable upside, equities research analysts plainly believe PepGen is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dyadic International has higher revenue and earnings than PepGen. Dyadic International is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
Dyadic International	$3.09M	11.41	-$7.36M	-$0.23	N/A

PepGen has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market.

Summary

PepGen beats Dyadic International on 9 of the 14 factors compared between the two stocks.

How does Dyadic International compare to Lixte Biotechnology?

Dyadic International (NASDAQ:DYAI) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lixte Biotechnology has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Lixte Biotechnology's return on equity of -134.91% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Lixte Biotechnology has lower revenue, but higher earnings than Dyadic International. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	11.41	-$7.36M	-$0.23	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

In the previous week, Dyadic International had 4 more articles in the media than Lixte Biotechnology. MarketBeat recorded 7 mentions for Dyadic International and 3 mentions for Lixte Biotechnology. Dyadic International's average media sentiment score of 0.00 equaled Lixte Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Dyadic International	Neutral
Lixte Biotechnology	Neutral

Dyadic International has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market.

Dyadic International presently has a consensus target price of $3.00, indicating a potential upside of 210.05%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Dyadic International beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.27M	$3.74B	$6.92B	$12.59B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-4.21	21.63	27.35	24.81
Price / Sales	11.41	179.77	507.73	89.92
Price / Cash	N/A	64.18	29.65	49.23
Price / Book	32.25	8.58	11.06	6.50
Net Income	-$7.36M	$23.68M	$3.57B	$336.03M
7 Day Performance	6.33%	4.17%	2.56%	2.68%
1 Month Performance	36.17%	16.07%	7.39%	5.50%
1 Year Performance	5.69%	63.53%	34.13%	25.01%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	2.376 of 5 stars	$0.97 +2.9%	$3.00 +210.0%	+3.9%	$34.27M	$3.09M	N/A	7	Gap Up
CUE Cue Biopharma	0.2502 of 5 stars	$31.56 +3.7%	N/A	-94.8%	$127.82M	$27.47M	N/A	60	High Trading Volume
PLYX Polaryx Therapeutics	1.9903 of 5 stars	$2.66 +5.1%	$10.00 +275.9%	N/A	$125.10M	N/A	N/A	11	Positive News
ALDX Aldeyra Therapeutics	3.1477 of 5 stars	$2.13 +3.9%	$5.50 +158.2%	-47.0%	$123.66M	N/A	N/A	10	News Coverage
PEPG PepGen	2.6025 of 5 stars	$1.80 +1.1%	$11.50 +538.9%	+54.9%	$123.12M	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 7/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. CUE, PLYX, ALDX, PEPG, and LIXT

How does Dyadic International compare to Cue Biopharma?

Summary

How does Dyadic International compare to Polaryx Therapeutics?

Summary

How does Dyadic International compare to Aldeyra Therapeutics?

Summary

How does Dyadic International compare to PepGen?

Summary

How does Dyadic International compare to Lixte Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. CUE, PLYX, ALDX, PEPG, and LIXT

How does Dyadic International compare to Cue Biopharma?

Which has more risk and volatility, CUE or DYAI?

Do analysts rate CUE or DYAI?

Does the media prefer CUE or DYAI?

Which has preferable valuation & earnings, CUE or DYAI?

Do insiders and institutionals hold more shares of CUE or DYAI?

Is CUE or DYAI more profitable?

Summary

How does Dyadic International compare to Polaryx Therapeutics?

Do analysts prefer PLYX or DYAI?

Is PLYX or DYAI more profitable?

Which has better earnings & valuation, PLYX or DYAI?

Does the media favor PLYX or DYAI?

Do insiders and institutionals believe in PLYX or DYAI?

Summary

How does Dyadic International compare to Aldeyra Therapeutics?

Is DYAI or ALDX more profitable?

Which has better valuation and earnings, DYAI or ALDX?

Does the media refer more to DYAI or ALDX?

Do analysts rate DYAI or ALDX?

Do insiders & institutionals believe in DYAI or ALDX?

Which has more volatility and risk, DYAI or ALDX?

Summary

How does Dyadic International compare to PepGen?

Does the media prefer PEPG or DYAI?

Do institutionals and insiders believe in PEPG or DYAI?

Is PEPG or DYAI more profitable?

Do analysts prefer PEPG or DYAI?

Which has preferable earnings and valuation, PEPG or DYAI?

Which has more risk and volatility, PEPG or DYAI?

Summary

How does Dyadic International compare to Lixte Biotechnology?

Do insiders and institutionals have more ownership in DYAI or LIXT?

Is DYAI or LIXT more profitable?

Which has better earnings and valuation, DYAI or LIXT?

Does the media favor DYAI or LIXT?

Which has more volatility & risk, DYAI or LIXT?

Do analysts recommend DYAI or LIXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools